Yet, these prior reports [12, 14, 32, 33] mentioned above have shown the KIR-ligand missing genotype as beneficial for patients’ responses, in part due to NK-mediated killing of tumor cells under conditions in which the inhibitory KIRs on the NK cells are not interacting with their corresponding inhibitory ligands on the tumor cells, thus being less inhibited [13]. This evidence concerns the gene KIR3DL1 and neoplasm.